American Journal of Botany and Bioengineering
https://biojournals.us/index.php/AJBP
ISSN: 2997-9331

The Use of Nanoparticles in Targeted Drug Delivery and Imaging in Oncology

Ali Abdul Hussein Musafir Khadir
University of Hillah Collage of Science Department of Medical Physics

Mohammed Jaafar Hamid Odeh, Zainab Mohammed Ali Muslim, Abdullah Abdul Wahid Hilan
University: Madinat Al-Elm College Madinat Al-Elm Department Medical Physics Science

Hussein jabbar Hamdullah habl
University of Wasit Collage of Science Department of General Physics

Received: 2024 19, Sep
Accepted: 2024 28, Sep
Published: 2024 18, Oct

Annotation: Oncology has been seeing a fairly dramatic shift towards targeted drug delivery, and the use of nanoparticles is the trend out in front. Many different types of nanoparticles are being investigated and used to deliver drugs directly to cancer cells and act as imaging agents to help care professionals diagnose and manage the course of the disease. Since some of the most promising methods today are also areas of study, there is a great deal of discovery each year in the way that nanoparticles can target cells, carry imaging agents, and treat small cancers in need of treatment. The central aim of the current study discusses the importance of the development of nanoparticles in targeted drug delivery and the enhanced efficacy of imaging systems, particularly in oncology. Obviously, this way of research application has a promising future in improving the lives of oncological patients. The second objective is to overview the outcomes of modern studies devoted to the application of nanoparticles as targeting drugs enhancing their effectiveness. Shadowing of passive targeting performed using the EPR effect will not be displayed since its effectiveness is not doubted nowadays. Likewise, there is a plethora of source

information on how long nanocarriers will keep providing accumulation in tumors. The means of treatment and diagnosis are steadily enhanced according to the recent advances in technological development in the bioscience fields, nanoengineering, and nanomaterials. Especially in oncology, where the increased mortality and morbidity rates continue to be a considerable problem all over the world, effective treatments and credible diagnostic methods are highly in demand. In fact, cancer is referred to as an evading disease at earlier stages, who also reinforce starting treatment at advanced stages with terrible disease outcomes, and they emphasize the urgent requirement for advancements to use a different approach in cancer care practices. Such advances are termed 'highly promising', which gains prominence in precision oncology approaches. This document could attract the reader and inspire them to read the whole document.

1. Introduction to Nanoparticles in Oncology

Nanoparticles (NPs) are a topic of significant interest in oncology. This is due to the extent of influence that these nanoscale structures can impart upon targeted drug delivery, efflux, retention within the tumor microenvironments, and molecular imaging. Of primary concern is the potential cooperativity that can exist between the basic sciences, the engineering of these systems, and clinical applications. For over 40 years, there have been reports that metal and dielectric NPs can interact with light in a manner that, in pertinent systems, was relatively novel. More recently, a wave of advances in nanoscience and nanotechnology has paved the way for continued yet increasingly refined study and practice. The use of NPs of many different materials for medical applications has proliferated; NPs of iron doped with cobalt, titanium, and silicon, gold, platinum, and metal-chalcogenides, to name but a few, have gained traction in the pre-clinical and some in clinical arenas of development.

That such a diversity should exist is indicative of the choice for the clinician and/or medical researcher as to how to proceed; medically adopted and sanctioned NPs are preferentially considered and give some indication as to the respective levels of progression for theranostic compounds. These, as a general rule, are FDA or EU approved carbon, lipid, polymer, or silicon-based nanostructures. It is within this climate of many potential choices that there exists a desire for evidence to support the interactions of these NP-centric systems with the biological systems into which they are to be integrated. Improved patient treatment and management may ultimately emerge from the development and utilization of these non-traditional pathways to site-specific delivery. If such agents are shown to present a reduced burden of side effects compared to their predecessors, the oncologist will have some greater freedom in the tailoring of delivery strategies and indeed oncological treatments to the parameters of hardware they hold. In terms of ongoing and future work, there remains considerable promise in translating pre-clinical data into the frequent clinical setting. In aiming for more traditional yet enhanced outcomes, we believe that

there will continue to be substantial pieces of work radiating from the topic of metal NP enhancements of traditional biological screening, diagnosis, and therapeutic treatments. [1][2]

1.1. Definition and Types of Nanoparticles

Nanoparticles – particles with two or three dimensions in the range of several to 100 nanometers, have attracted attention in the fields of targeted drug delivery and imaging. Typically, nanotechnology deals with particles in the size range between 1 and 100 nanometers. This is because as the order of the particle size approaches the several-nanometer scale and goes lower than that range, a phenomenon of quantum effect occurs. This gives the nanoparticle several special properties that are quite distinct from bulk or fine powder.

Liposomes, dendrimers, micellar nanoparticles, and polymeric nanoparticles are some of the biodegradable and biocompatible nanocarriers. The potential application values of this vast variety of nanocarriers are in developing drug delivery systems as well as imaging techniques in the field of oncology. In order to prevent the reticulo-endothelial system (RES) uptake, hydrophilic surface-modified nanocarriers such as PEGylated liposomes are preferred because they are non-toxic, non-immunogenic, non-antigenic, and contain unique biological properties. Furthermore, they have the ability to easily escape from detection by the RES of the organs. The stealth nanocarrier has a slow blood clearance rate, reduced drug uptake by the hepatocytes and Kupffer cells by way of intravenous applications, and is capable of drug accumulation in the target site for a long duration. Polymeric nanoparticles and plasmon-resistant exteriors have preferential application in magnetic resonance imaging (MRI) because of their high transverse relaxivity and ability to load significant amounts of MR contrast agents.

Most cell types, especially the endothelium, allow hydrophobic substances to be directly transported via an endosome transcytosis mechanism during the formation of vesicular compartments. Conversely, the targeting capability of these systems was observed to be reduced as a result of the aggregation of the nanoparticles, and it may be due to their relatively larger size. Although size reduction is feasible, the surface properties of the nanoparticles are of primary importance, as the nanoparticle will play the major role in interacting with biological molecules and cells. Several surface modifications of nanoparticles have been studied that allow the nanoparticles to be valves themselves and that can be tailored to perform the reactions they are needed for in their environment. [3][4]

1.2. Rationale for Nanoparticle Use in Oncology

Cancer conditions emphasize the necessity for specific treatments, which can be achieved with nanoparticles. An overview of the subject is given alongside nanotechnology and cancer statistics. Basic steps of the rationale are outlined, underlying the concerns that have ignited the interest in nanomedicine and justify this work, including the failure of conventional cancer treatments, the vast differences in clinical outcomes observed in patients that are treated in parallel, and underlying issues in cancer drug treatments. Cancer itself can lead to physical and biological barriers for the targeted delivery of therapeutics. To fight these odds, nanoparticles can be engineered.

Nanoparticles are more stable, can modify solubility, and can encapsulate a greater quantity of drugs than the drugs themselves. They have a promising potential to passively accumulate in the morbid tissue and/or cells as a result of the enhanced permeability and retention effect. Moreover, nanoparticles can be tuned to be 'smart', exploiting one or more of the unique features of the biological microenvironment of tumors to trigger the drug release on the spot, which can further increase their efficacy. Nanoparticle-based drug systems have portrayed faster and sustained pharmacokinetics, improved safety profiles compared to free drugs, a reduced prevalence of dose-related toxicities, and a better quality of life for cancer patients. Nanoparticles can also be designed to bear on their surface molecules that can improve targeting towards tumor cells and tissues, potentially further increasing drug efficacy and reducing adverse events. [5][6]

Nanoparticles alone, and in many cases, in addition to imaging modalities for multimodal imaging,

are used as contrast agents. Magnetic and gold nanotechnologies are used to enhance Magnetic Resonance Imaging, while others can be used to improve Computed Tomography. Iron and bismuth nanoparticles could be used as contrast agents during both fluoroscopy, high-resolution SPECT, and/or accurate 3D absorbed dose calculations, while gadolinium nanoparticles have been used for SPECT imaging. Furthermore, the atomic arrangement and density of certain nanoparticles make them very promising materials for high-resolution, high-sensitive physical modalities imaging such as photoacoustic imaging or optoacoustic imaging.

2. Principles of Targeted Drug Delivery

The past decades have been marked by rapid growth in the development of anticancer drug delivery systems (DDSs) with the ability to target tumor necrotic zones or specific molecular markers on the surface of cancer cells. To enhance their effectiveness and decrease systemic side effects, innovative targeted DDSs need to be invented and approved for clinical use. The proposed ideal system would deliver a large quantity of therapeutic agents specifically to the tumor cells, with minimal side effects on healthy tissues. According to classical concepts, the specific targeting of drugs and disease detection is based on the local administration of pharmaceutical agents together with a biologically active carrier. Drug targeting can be categorized as passive and active. Moreover, it is necessary to take into account the risks and benefits of using nanobiotechnology to fundamentally improve the lives of patients with cancer.

Passive targeting refers to the drug liberation and penetration processes into the targeted tumor tissue or organs, targeting pathological locations due only to the selective properties of the pharmaceutical substances such as size, half-life in circulation, solubility, physicochemical properties, or other molecular features. Different from passive targeting, which is biologically regulated, active targeting refers to the recognition and binding of drugs and pharmaceutical agents specific for a certain stage of molecular receptors on the target tissue cells. For most tumor cells, active uptake takes place through receptor-mediated endocytosis. Potential tumor molecular markers can be the functions of signaling pathways, nuclear medicine markers, or membrane-based markers. Targeting the microenvironment should also be considered for effective delivery of anticancer drugs. For example, anticancer drugs can also be designed to target the vasculature of a tumor or angiogenesis. The use of nanometer-sized drug carriers can extend the residence time of anticancer drugs in the blood compartment, and therefore increase the probability of drug accumulation in and around tumor tissues. The pharmacokinetics of a drug and its distribution depend on the size of drug carriers, route of administration, and the surface properties of the carriers, as well as the nature and composition of the surrounding environment. However, the general challenges for efficient drug delivery are multiple drug resistance and the limitations that heterogeneity within a tumor mass imposes. Through targeted delivery strategies, the rapid development and application of imaging and sensing are used to early detect and precisely stage cancer, monitor response to treatment, and provide enhanced treatment quality to prolong and improve patients' survival. Thus, the significant needs for using nanobiotics in cancer therapy could be foreseen. [7][8][9]

2.1. Importance of Targeted Drug Delivery in Oncology

Targeted drug delivery is of special interest in oncology, wherein even small doses of systemic chemotherapy result in considerable toxicity; thus, drugs are given at doses below their maximum tolerated limits. The need for multiple such cycles not only increases the treatment cost but also leads to decreased patient compliance. Hence, newer approaches that can target drugs specifically to the tumor are required. A few drugs currently under investigation for use in cancer are known to have serious side effects when given in a conventional manner. Some conventional chemotherapeutic drugs are not active unless metabolized by the liver in vivo. As a result, the drug levels in the bloodstream must remain high enough for the liver to act upon the drug. This may cause a decrease in the drug's potential to enter the tumor.

Targeted therapies may provide increased effectiveness in comparison to conventional drugs. A

number of such drugs are presently part of therapy for certain cancers. In the case of lung cancer, for instance, the mutation status of the EGFR gene determines whether a patient will be given the targeted therapy or conventional chemotherapy. The targeted therapy is an EGFR tyrosine kinase inhibitor that blocks EGFR on the surface of the cell. The cancer cells develop signaling pathways such as EGFR that initiate several survival signals to start the development of the tumor. Targeting EGFR will result in delivering therapy with molecular specification, increasing the efficacy of the agent. Such tumor-killing agents are developed in the laboratory in accordance with the cell's surface receptors that they recognize as foreign molecules to the body. Nanotechnology is believed to become a paramount element of improvements in several applications of oncology in the future. The engineering of nanoparticles has advantages with the well-known application for delivering various drugs to cancerous masses. Nanoparticles—mainly metal nanoparticles—are applied for imaging in cancer case-sensitive tests. The tiny size of nanoparticles makes them suitable for studying intracellular processes and molecular brain imaging following crossing the blood-brain barrier. [10][11]

2.2. Challenges and Solutions in Targeting Tumor Cells

Recently, the effectiveness of various drug delivery systems in targeting tumor cells has been shown. However, these systems have a number of limitations that prevent achieving the optimal therapeutic effect. One of these problems is the heterogeneous distribution of nanodrugs in a solid tumor; this is due to the heterogeneity of tumor cells and the tumor microenvironment. An additional problem associated with modern therapy in the brain is that the capillaries of the brain form the blood-brain barrier. The tumor microenvironment is not only different for different types and stages of oncological diseases but can even vary in different regions of the same tumor. It is in the most poorly vascularized areas of the tumor that the solid stress that develops in a malignant neoplasm inhibits the blood vessels so much that it prevents the penetration of drugs in an unmodified form, including drug delivery systems. As a consequence, the poorly vascularized parts of the tumor are not washed by the blood, so the pH is lower than in well-vascularized areas, approximately 6.8–7.2. Because of solid stress, the pH in some regions increases to 7.4, but in some areas, which are far from the penetration of the macromolecules forming the drug delivery systems, the pH rises to 7.7–8.0. This area of the tumor makes up about 2% of the tumor volume and is inhospitable for the imposed therapy, which is usually facilitated by the functionalization of drug delivery systems.

Another problem is the drug resistance that occurs during conventional chemotherapy and the use of nanoparticles. Heterogeneity in some cancer types or in an individual patient may lead to therapy failure. Nanodrugs decrease the multidrug resistance but are not sufficiently effective, so at present, combination therapy (conventional chemotherapy and immunotherapy or gene therapy, including chemotherapy with nanoparticles) receives more attention. Most treatment-associated disadvantages could be overcome by improving the specificity of drug delivery systems to tumors, which requires not only a deeper understanding of nanodrug biodistribution and pharmacodynamics but also further development of multifunctional nanodrugs. Unfortunately, a successful strategy for improving drug delivery systems for tumors can be true only temporarily. Tumor cells, including the tumor stem cells, may transform, and the tumor tissue developed differently with other microenvironments requires innovative therapy and new nanodrugs with different properties. Therefore, it is necessary to continuously improve nanotechnology to develop new, highly specific drug formulations for currently available medications, in addition to developing more and more dynamic immunotherapy and gene therapy. [12][13]

3. Imaging Techniques in Oncology

Imaging techniques are an essential part of oncology to provide accurate diagnosis and follow-up of patients during therapy. Several imaging techniques are used in practice, including morphological and functional studies. The most employed morphological studies are magnetic resonance imaging, computed tomography, and ultrasound. Also, PET/CT is today the most used

nuclear medicine imaging modality in oncology, which has its strength in the functional study thanks to the use of tracers. For further study of some tumors, traditional histological findings have limitations; new imaging techniques are present today. MR spectroscopy or diffusion, PET-MR, and contrast-enhanced ultrasound are some of the advanced studies used in oncology for their good contribution to the treatment of these patients.

Morphological imaging studies have great importance in the diagnosis of many tumors. MRI is useful in the study of brain, neuroendocrine tumors, gynecological, and other cancers. It plays an equally important role to CT in some diseases. MRI has excellent contrast in the soft tissue of the human body, a high spatial resolution without radiation input, and produces high-quality three-dimensional images. CT is used in the study of diseases in the abdomen, thorax, chest, and others such as bone. It is commonly used for follow-up in oncology. Spiral CT gives a short time and high-resolution scan of the body in a few seconds using intravenous iodine-based contrast media when examining different diseases. PET/CT is widely applied in the diagnosis and monitoring of cancer patients. The modality combines functional and anatomical imaging acquired in a single unit with minimal time interval. Oncological patients can get a dual benefit from PET/CT because of the broad application of these combined investigations. However, PET/CT has some limitations in its spatial resolution and is also an expensive technique with high radiation exposure for the patient subjects. In order to acquire an even clearer image of the body, researchers and scientists want to reduce the time that contrast media stay inside the patient's body, a positive approach to the reduction in the volume of contrast. When researchers work on this project, the time of cancer diagnosis will be shortened, and that will give more hope to patients to heal. [14][15]

3.1. Overview of Imaging Modalities in Oncology

The arsenal of available imaging modalities has been expanding in the last few decades, and each modality has strengths and weaknesses. An X-ray has been used for centuries, while ultrasound, MRI, and CT are the more recent techniques. The X-ray is excellent at detecting abnormalities like fractures and foreign bodies. These X-rays are vastly different from those used in CT. Fluoroscopy resembles an X-ray but with continuous visualization, including motion. Ultrasound is excellent for certain indications, including vascular imaging, fetal imaging, and soft tissue musculoskeletal imaging. MRIs visualize any part of the body. Another technique is CT. In the oncological sense, CT proves beneficial to identify tumors, nodal involvement, and if tumors invade locally. MRI has better magnetic and spatial resolution among other features, while there are areas where it may not be advantageous.

There are some techniques now capable of combining two of the current modalities: PET-CT and PET-MRI. Nuclear imaging uses isotope tracers and gamma cameras or positron emission event detection. In the non-oncological sector, the introduction of FDG revolutionized diagnostic radiology and oncology. Regular PET is evolving toward PET-MR. There is also the advent of explicit visualization of various molecules in the body, such as peptide and tyrosine kinase lesion imaging, a molecular layer over the anatomical structures. The additional information from these imaging methods has made them indispensable in patient management, especially in oncology. Whether there is a hepatic lesion is one issue; there have been numerous studies to reveal appropriate treatment. The best response or result is also written as having to be defined by imaging. It is the point when surgery, ablative intervention, or chemotherapy may be initiated in the clinical pathway. Moreover, it is the indicator of disease recurrence. [16][17]

3.2. Role of Nanoparticles in Enhancing Imaging

Despite serving as the cornerstone for early cancer management, an accurate diagnosis could not be ascertained with the available imaging modalities due to insufficient sensitivity and specificity. With unique multifunctional properties that facilitate easy localization and target-specific actions, nanoparticles offer exceptional tuning options to improve diagnostic accuracy by enhancing the sensitivity and specificity of an imaging modality. They can be used to generate contrast that can enhance imaging signals. Nanoparticles could also be used as theranostic agents that combine

specific pathway-related targeting with imaging and therapeutic interventions for close to real-time assessment of their effectiveness. Imaging techniques have great potential for providing disease diagnosis without the need for histological samples. The development of fluorescent or molecular probes may allow for attached or incorporated nanoparticles or molecules to become selectively taken up by the tumor cell. Encapsulating nanoparticles into a liposome allows for a greater range of functionality, such as the attachment of hydrophilic targeting moieties to make liposomes stealthy. Stealth liposomes have a reduced susceptibility to uptake by the reticuloendothelial system and an effect of a longer circulating lifetime. Coupled with improved optical imaging for the detection of these particles for both locating the tumor intraoperatively and for preoperative lesion site identification, there has been continued interest in techniques to enable image-guided surgery. The capability of using fluorescence imaging to visually guide the surgeon intraoperatively has been evaluated in clinical studies with improved sensitivity and specificity. Other nanoparticle-based imaging capabilities, such as the development of atherosclerotic plaque vulnerable to rupture, have resulted in an r(2)-weighted MRI with a sensitivity of 94% for the detection of lipid cores. Other potential nanoparticle-based imaging approaches involve computed tomography, X-ray, ultrasound, and PET with modified cyclodextrin derived from very low-density lipoprotein. [18][19]

4. Case Studies and Applications

Case Studies and Applications. The practical applications of the concepts are illustrated via the following case studies. The studies discuss only selected groups of nanoparticles and their application as drug carriers and diagnostic agents in treating cancer. The sections of the case studies discuss the currently approved nanoparticles and explore the clinical studies for each type of cancer that pertains to the pharmaceutical market surveillance. The applications describe the state of the art of nanotheranostics in each type of cancer. To provide an overview of the cancer field, the most occurring or lethal type of cancer and curative or common pharmaceuticals that are employed are discussed. Depending on the type of cancer or the volume of space to be treated, nanoparticles covering complexation and drug-releasing characteristics are now valuable.

The most used administration of nanoparticles is through the intravenous route due to their EPR effect; however, other routes for nanoparticles have been researched. Applications from three main categories of nanoparticles are selected that are also currently occurring for the treatment of different cancers and include DOTMA/DOPE, DMPG/DSPE-PEG, or DMPG/Chol with the anti-cancer drug etoposide phosphate as the pharmaceutical. Recommendations for future work are provided after identifying the problems that occur in clinical studies. With the advancements in treatment modalities such as surgery, radiation therapy, and chemotherapy, the diagnostic tools and treatment approaches for cancer are continually growing. Inspired by the transformation that takes place in the field of oncology, specific nanoparticles, or so-called materials, have been designed for targeting the cancer cells to release the drug locally, initiate the localized release of the chemodrug, antibody, DNA, or the catalysis of hypoxia synergistic enzymes, and stimulate the synergistic reduction, glutathione, and acidic environment in the treatment of cancer as well as the use of localized loadings in the cancer photothermal treatment. [20][21]

4.1. Current Nanoparticle-based Therapies in Oncology

Nanoparticles possess exceptional properties that allow them to selectively enter and accumulate in tumors post-intravenous administration. In this subsection, we discuss current nanoparticle-based oncologic therapies both on the market and in clinical trials. Liposomes are a type of nanoparticle utilized in oncologic therapies that are widely used and are an approved product for certain types of cancer. Doxil is one of the most well-known liposomal therapies, and it uses PEGylated liposomes loaded with doxorubicin to treat ovarian cancer, Kaposi’s sarcoma, and multiple myeloma. Micelles are a form of nanoparticle also in clinical use today. As far as is known, no micellar therapies have been approved to date, and a phase 3 trial evaluating GEN1046 in metastatic breast cancer is ongoing. Dendrimers have also been utilized in oncologic therapies.

Certain companies have developed cancer chemotherapeutics that use dendrimers to encase the chemotherapy drug to prevent tumor growth.

Nanoparticles are bio-nanomaterials that are primarily developed to diagnose and treat cancer. They were once a tool for experimental materials. However, now they are in transition to become the therapeutic armamentarium of cancer research and care. They are widely applied in targeted chemotherapy, molecular imaging, radiotherapy, and anticancer drug and gene delivery. Multifunctional nanoparticles now show the specific pathways through which drugs can reach the target and induce cancer cell initiation of apoptosis. These nanoparticle-based systems are usually being formulated for lung and prostate cancers, and some are even approved in other countries. These include Doxil for ovarian cancer, Abraxane for breast, pancreatic, and lung cancers, Marqibo for lymphoma, DaunoXome for HIV-related Kaposi's sarcoma, and Onivyde for unresectable pancreatic cancer in combination with other therapeutic agents. The main advantage of nanomaterials in therapy is a clinical-area-specific expression of certain biomarkers; in some cases, the patient and disease staging are predictive determinants of outcomes. [22][23]

4.2. Successful Clinical Trials and Future Directions

There are several clinical trials that have seen success in treating oncological diseases that demonstrate utility with nanoparticles. The first to reach success was the use of a liposomal doxorubicin in treating Kaposi's sarcoma within acquired immunodeficiency syndrome, and other liposomes have shown benefit in acute myeloid leukemia. Furthermore, there have been over 20 studies started incorporating microbubble technology for imaging of intraocular cancers such as retinoblastoma and uveal melanoma. These successes give a clear indication that there are already as well as potentially new ways to treat cancer patients in the future. Several ongoing clinical trials continue to promise how nanoparticles can further improve patient outcomes. Of them, a trial uses a liposomal irinotecan in combination with a leukocyte inhibition molecule inhibitor in treating colon cancer and has attracted patients, furthering the application of drug delivery to patients at large. Furthermore, the nanoparticle-albumin-bound paclitaxel in combination with immunotherapy have gained radiographical responses within studies in rare prostatic and urothelial cancers, suggesting potential to treat these patients in the future.

A great deal of forethought is required as we continue the interest in nanoparticles for drug delivery and imaging. Certainly, some regulations prevent advancing this frontier, as our current good manufacturing practices are simply not intended to scale and incorporate predictive features necessary for the ever-expanding precision. Although the aforementioned lipid impenetrability has seen some success, the future design of all nanoparticle surfaces warrants investigation. In sum, innovative technologies and significant collaborations will be required to master these potential roadblocks of investment for simplicity in scale for many industries. This will certainly present significant challenges over a full range of pharmacy disciplines. Working across these lines will also require education across all parties regarding the aforementioned concerns, including direct participation of patient advocates to address issues related to administering nanoparticles in clinical settings. In closing, increasingly sensitive analytic techniques underscore the importance of continued investment and clinical trials within the industry to produce necessary technologies advancing precision medicine. Moving forward, a nanotechnology-enhanced future seems to be on the horizon. [24][25]

5. Ethical and Safety Considerations

- Introduction. Over the past decade, there has been an increasing number of reports that have raised concerns regarding the potential risks and uncertainties associated with the increased usage and exposure to nanoparticles in fundamental, preclinical, and first-in-human trials. We systematically analyzed and reviewed the current knowledge with respect to the potential safety considerations of nanoparticles in preclinical and clinical studies. This part gives an overview of the existing regulatory framework for the use of nanoparticles in oncology. The ethical benefits and harm balance are also discussed and analyzed.

- Nanoparticle formulations for cancer therapy are governed by the same regulatory requirements as chemical entities and biopharmaceuticals. The applications and testing methods may thus differ from testing biologicals or small molecules, but the experimental regimens must be compliant with the national regulations as they apply to the investigator. While drugs are widely dominated by small molecules and biologicals, nanoparticles tested today include a variety of material classes, among them nano-metal oxides, rods, particles, or platinum drugs. While patients in clinical trials with these novel anticancer therapeutics will benefit from the possible direct and indirect advantages, it is also important to discuss and critically reflect from the patient-physician perspective and in a more general context, the inevitable risks and uncertainties. For the clinical approval of traditional drugs, rigorously tested wholesomeness is a longstanding approach to keep exposure to unpredicted health risks to a minimum. We argue that the exemplified approach of rigorous particle wholesomeness and risk examinations must be carefully and rigorously reviewed by experts from the fields of clinical research, experimental and social oncology, ethical committees, and the public. Not doing so and neglecting widespread security tests as involving a general exemption would not only pose potential health risks to the patients but also constitute an asymmetry of scientific advice among academia, research organizations, market mechanisms, and consumer society. [26][27][28]

5.1. Regulatory Frameworks for Nanoparticle Use in Oncology

Until today, in the field of oncology, several regulatory frameworks have been established for the use of nanoparticles in the diagnosis and treatment of different tumors. The European Union is one of the pioneering regulatory institutions in the approval of nanomedicines. A reflection paper was created proposing that the process for evaluating the quality, safety, and efficacy of medicines containing new nanomaterials should be well-documented to provide clear points of reference for regulation. Finally, the reflection paper has been released for public comment as an annex to guidelines on the quality of nanomedicines. The production process for new materials often deviates significantly from current regulatory norms for conventional medicines. For this reason, the safety and quality of all these products must be carefully evaluated before their use in humans is considered. Regardless of the origin or classification of nanoparticles, a comprehensive plan for the research and development of nanoparticle-based diagnostic techniques and nanostructured drug delivery systems will always be contingent on the prevailing laws and policies of the specific geographical location.

The ongoing development of nanotechnology has brought several regulatory, ethical, and societal challenges. Because nanomedicine and its predecessor, conventional medicine, are not identical, however, the physical sites and mechanisms of action of nanoparticles necessitate certain amendments in the regulatory trials. An exhaustive definition of new biological characteristics and a procedure for rating fresh data are must-haves for nanoparticle-related treatment. Improved chemistry and dosing processes might also call for novel, more appropriate methodologies for the purposes of diagnosis and treatment. This scientific advancement will also necessitate submitting clinical trial applications, which will include a proposal for methodologies and statistical analysis techniques that are compatible with the basic pharmacological models produced by nanotechnology. Given that organisms respond based on their size and mode of presentation, it is essential to develop insightful mechanisms for ascertaining particle-specific toxicology inputs. One way to ensure the safe use of nanoparticles in the emerging nanoparticle-related industries is to investigate a scenario of a distinct nanoparticle through a so-called "intelligent toxicology." The major stakeholders in regulatory research are regulatory agencies that are responsible for reducing the degree of disability-related lethargy as well as the premium costs associated with product indiscretion. Researchers, industrialists, and health professionals must ultimately follow the declaration of regulatory bodies in order to introduce regulatory-compatible products. Therefore, the centralized regulatory authority will be a worthwhile portal of access to the industrial and medical settings. Regulatory ballasting will not only contribute to the sustenance of an ethical and

economic nanoparticle-related research environment, but it will also produce a promising regulatory system for scholars to embrace. [29][30]

6. Conclusion

We believe that nanoparticles particularly have given us faster and clearer results in cancer localization and treatment. Moreover, the use of nanotechnology facilitates still image-based characterization of tissues and molecular processes that can aid significantly in cancer staging and also in information guidance for personalized therapies. However, considering the challenges that come with this technology, a multidisciplinary partnership is the most likely way to harness all the potentials of NPs. Therefore, oncology researchers need to be open to these new ideas, innovations, and advancements. Likewise, as there is sharing for goodness, a wealth of information will inspire and enlighten both the academia and pharmaceutical industries to give importance on the safe and active targeting of cancer drugs by introducing concerned and frequently prescription drugs and surfactants suited for the manufacturing of nanoparticles. This would, at last, play a tiny role in the formulation of a healthy and manageable policy. To date, we have witnessed substantial advancements in the development of various nanoparticles in theranostics. Furthermore, extraordinary benefits of nanoparticles are obvious and promising for the development of the CT, MRI, and PET in clinical applications. For future research strategies on the potential of the nanoparticles in personalized medicine, we argue that there is insufficient evidence that is available for the quantitative synthesis of personalized predatory signaling based therapy approaches. The role and functionality of multidisciplinary teams and development novel drug models should also be included.

References:

1. X. Ma and A. Poma, "Clinical translation and envisioned impact of nanotech for infection control: Economy, government policy and public awareness," Nanotechnology Tools for Infection Control, 2025. [HTML]
2. K. Rangesh, M. Anand, S. Padmapriya, "Current Advances in the Use of Functionalized Nanoparticles for the Diagnosis and Treatment of Microbial Infections in Aquaculture," … for Smart Prevention …, 2024. [HTML]
3. R. Zein, W. Sharrouf, and K. Selting, "Physical properties of nanoparticles that result in improved cancer targeting," Journal of Oncology, 2020. wiley.com
4. A. A. Yetisgin, S. Cetinel, M. Zuvin, A. Kosar et al., "Therapeutic nanoparticles and their targeted delivery applications," Molecules, 2020. mdpi.com
5. H. Yang, Z. Tong, S. Sun, and Z. Mao, "Enhancement of tumour penetration by nanomedicines through strategies based on transport processes and barriers," Journal of Controlled Release, 2020. [HTML]
6. F. Passaro, C. G. Tocchetti, G. Spinetti, F. Paudice, "Targeting fibrosis in the failing heart with nanoparticles," Advanced Drug Delivery, 2021. [HTML]
7. S. Kunjiappan, P. Pavadai, S. Vellaichamy, "Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: A state-of-the-art review," Drug Development, 2021. [HTML]
8. X. Wang, Y. Qiu, M. Wang, C. Zhang, and T. Zhang, "Endocytosis and organelle targeting of nanomedicines in cancer therapy," *International Journal*, 2020. tandfonline.com
9. B. Banushi, S. R. Joseph, B. Lum, and J. J. Lee, "Endocytosis in cancer and cancer therapy," *Reviews Cancer*, 2023. researchgate.net
10. G. P. Gakis, I. G. Aviziotis, and C. A. Charitidis, "Metal and metal oxide nanoparticle toxicity: moving towards a more holistic structure–activity approach," Environmental Science: Nano, 2023. rsc.org

11. R. S. Lekshmi et al., "Europium (III) Incorporated Bovine Serum Albumin Stabilized Gold Nanoclusters as Fluorescent Probes for the Detection of Sarcosine, a Prostate Cancer Biomarker," 2023. [HTML]
12. S. Liu, A. R. Khan, X. Yang, B. Dong, J. Ji, and G. Zhai, "The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy," *Journal of Controlled Release*, 2021. [HTML]
13. H. Tan, M. Zhang, Y. Wang, P. Timashev, and Y. Zhang, "Innovative nanochemotherapy for overcoming cancer multidrug resistance," 2021. [HTML]
14. J. M. Algarín, E. Díaz-Caballero, J. Borreguero, F. Galve, "Simultaneous imaging of hard and soft biological tissues in a low-field dental MRI scanner," Scientific Reports, 2020. nature.com
15. F. A. Huber, F. Del Grande, and S. Rizzo, "MRI in the assessment of adipose tissues and muscle composition: how to use it," *… imaging in medicine …*, 2020. nih.gov
16. S. P. Rowe and M. G. Pomper, "Molecular imaging in oncology: Current impact and future directions," CA: a cancer journal for clinicians, 2022. wiley.com
17. L. Bodei, K. Herrmann, H. Schöder, and A. M. Scott, "Radiotheranostics in oncology: current challenges and emerging opportunities," *Clinical Oncology*, 2022. nih.gov
18. TT Truong, S Mondal, VHM Doan, S Tak, and J Choi, "Precision-engineered metal and metal-oxide nanoparticles for biomedical imaging and healthcare applications," *Advances in Colloid and Interface Science*, 2024. [HTML]
19. A. A. Ansari, A. K. Parchur, N. D. Thorat, and G. Chen, "New advances in pre-clinical diagnostic imaging perspectives of functionalized upconversion nanoparticle-based nanomedicine," *Coordination Chemistry*, 2021. [HTML]
20. P. Zhang, Y. Li, W. Tang, J. Zhao et al., "Theranostic nanoparticles with disease-specific administration strategies," Nano Today, 2022. rice.edu
21. A. Al Shoyaib, S. R. Archie, and V. T. Karamyan, "Intraperitoneal route of drug administration: should it be used in experimental animal studies?," Pharmaceutical research, 2020. springer.com
22. E. Pavitra, B. Dariya, G. Srivani, S. M. Kang, and A. Alam, "Engineered nanoparticles for imaging and drug delivery in colorectal cancer," Seminars in Cancer, 2021. [HTML]
23. S. Raj, S. Khurana, R. Choudhari, and K. K. Kesari, "Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy," Seminars in Cancer, Elsevier, 2021. aalto.fi
24. H. K. Gardner and I. A. Matviak, "Smarter Collaboration: A New Approach to Breaking Down Barriers and Transforming Work," 2022. [HTML]
25. R. G. Cooper, "Overcoming Roadblocks to AI Adoption in Innovation," Research-Technology Management, 2024. researchgate.net
26. K. Elumalai, S. Srinivasan, and A. Shanmugam, "Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment," Biomedical Technology, 2024. sciencedirect.com
27. S. Wang, K. Cheng, K. Chen, C. Xu, P. Ma, and G. Dang, "Nanoparticle-based medicines in clinical cancer therapy," Nano Today, Elsevier, 2022. google.com
28. S. Gavas, S. Quazi, and T. M. Karpiński, "Nanoparticles for cancer therapy: current progress and challenges," Nanoscale research letters, 2021. springer.com
29. H. Huang, W. Feng, Y. Chen, and J. Shi, "Inorganic nanoparticles in clinical trials and translations," Nano today, 2020. [HTML]
30. A. A. Halwani, "Development of pharmaceutical nanomedicines: from the bench to the market," Pharmaceutics, 2022. mdpi.com